Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Receives Consensus Rating of "Hold" from Brokerages

Key Points

• Consensus "Hold" — Nine analysts cover Amphastar (1 sell, 6 hold, 2 buy) with an average 12‑month target of $27.43.
• Most recent quarter missed expectations (EPS $0.73 vs. $0.97; revenue $183.11M vs. $190.48M), triggering multiple price‑target cuts and at least one downgrade.
• The stock trades near $21.88 with a market cap ~ $974M, P/E ~10.8, 52‑week range $17.03–$31.26, and roughly 65% institutional ownership.

Shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Get Free Report) have been given a consensus rating of "Hold" by the nine ratings firms that are covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and two have given a buy rating to the company. The average 12-month target price among brokers that have issued a report on the stock in the last year is $27.4286.

Several equities research analysts recently issued reports on the stock. Barclays dropped their target price on shares of Amphastar Pharmaceuticals from $30.00 to $23.00 and set an "equal weight" rating on the stock in a report on Wednesday, April 8th. Weiss Ratings cut Amphastar Pharmaceuticals from a "hold (c-)" rating to a "sell (d+)" rating in a report on Friday, April 10th. Wells Fargo & Company dropped their price target on Amphastar Pharmaceuticals from $34.00 to $30.00 and set an "overweight" rating on the stock in a research note on Friday, February 27th. Jefferies Financial Group reaffirmed a "hold" rating and issued a $22.00 price objective (down from $30.00) on shares of Amphastar Pharmaceuticals in a report on Tuesday, April 21st. Finally, Needham & Company LLC reduced their price objective on Amphastar Pharmaceuticals from $34.00 to $30.00 and set a "buy" rating for the company in a research report on Friday, February 27th.

Amphastar Pharmaceuticals Price Performance

Shares of NASDAQ:AMPH opened at $21.88 on Friday. The company has a debt-to-equity ratio of 0.77, a quick ratio of 2.90 and a current ratio of 4.02. The firm has a market cap of $974.32 million, a price-to-earnings ratio of 10.78, a price-to-earnings-growth ratio of 1.77 and a beta of 0.97. The business has a 50-day simple moving average of $21.04 and a two-hundred day simple moving average of $24.56. Amphastar Pharmaceuticals has a fifty-two week low of $17.03 and a fifty-two week high of $31.26.

Amphastar Pharmaceuticals (NASDAQ:AMPH - Get Free Report) last announced its quarterly earnings results on Thursday, February 26th. The company reported $0.73 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.97 by ($0.24). Amphastar Pharmaceuticals had a net margin of 13.63% and a return on equity of 17.58%. The company had revenue of $183.11 million for the quarter, compared to analysts' expectations of $190.48 million. On average, analysts expect that Amphastar Pharmaceuticals will post 2.93 earnings per share for the current year.

Institutional Investors Weigh In On Amphastar Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the business. Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of Amphastar Pharmaceuticals by 24.2% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,233 shares of the company's stock worth $60,000 after buying an additional 435 shares during the last quarter. Farther Finance Advisors LLC raised its position in Amphastar Pharmaceuticals by 46.3% in the fourth quarter. Farther Finance Advisors LLC now owns 1,381 shares of the company's stock worth $37,000 after acquiring an additional 437 shares during the period. ProShare Advisors LLC raised its position in Amphastar Pharmaceuticals by 5.3% in the fourth quarter. ProShare Advisors LLC now owns 9,083 shares of the company's stock worth $243,000 after acquiring an additional 457 shares during the period. Los Angeles Capital Management LLC boosted its stake in shares of Amphastar Pharmaceuticals by 2.4% during the 4th quarter. Los Angeles Capital Management LLC now owns 19,397 shares of the company's stock worth $478,000 after acquiring an additional 459 shares during the last quarter. Finally, GAMMA Investing LLC grew its position in shares of Amphastar Pharmaceuticals by 37.8% during the 4th quarter. GAMMA Investing LLC now owns 1,685 shares of the company's stock valued at $45,000 after acquiring an additional 462 shares during the period. Hedge funds and other institutional investors own 65.09% of the company's stock.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company headquartered in Rancho Cucamonga, California. Founded in 2004, Amphastar focuses on the development, manufacturing and commercialization of injectable and inhalation products. The company's manufacturing facilities in California produce both generic and proprietary formulations designed to address urgent and chronic medical conditions.

Amphastar's portfolio includes a range of injectable generics such as epinephrine, naloxone and lidocaine, serving hospital, emergency medical and retail pharmacy channels.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.